Skip to content

Clinical trials

Phase 3 Hyperlipoproteinemia Type II trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperlipoproteinemia Type II Phase: Phase 3 Country / region: United States Clear all

26 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20052
20061
20071
20082
20092
20101
20151
20163
20201
20211
20222
20233
20242
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed20
Recruiting4
Enrolling by invitation1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Pfizer4
Kastle Therapeutics, LLC3
NewAmsterdam Pharma3
Novartis Pharmaceuticals3
Amgen2
AstraZeneca2
Esperion Therapeutics, Inc.2
Merck Sharp & Dohme LLC2
Aegerion Pharmaceuticals, Inc.1
Arrowhead Pharmaceuticals1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperlipoproteinemia Type II26
Hypercholesterolemia16
Hyperlipidemias9
Dyslipidemias8
Homozygous Familial Hypercholesterolemia7
Genetic Diseases, Inborn5
Atherosclerosis4
Hyperlipoproteinemias4
Lipid Metabolism Disorders4
Lipid Metabolism, Inborn Errors4

Trials

Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.